Neuroplasticity and Psychedelics: How These Compounds May Rewire the Brain

# Neuroplasticity and Psychedelics: How These Compounds May Rewire the Brain

If there's one concept that explains why so many researchers are excited about psychedelic medicine, it's neuroplasticity — the brain's ability to form new neural connections and reorganize existing ones.

Depression, PTSD, addiction, and chronic anxiety all share a common feature: rigid patterns of brain activity. The same circuits fire in the same ways, producing the same thoughts, feelings, and behaviors. Psychedelics appear to temporarily disrupt these patterns and promote the growth of new connections — essentially opening a window of enhanced plasticity that, with proper therapeutic support, can lead to lasting change.

What neuroplasticity actually means

Your brain is not static. It's constantly rewiring — strengthening connections you use frequently and pruning ones you don't. This is how you learn, form memories, and adapt to new situations.

But neuroplasticity isn't always beneficial. In depression, the brain can wire itself into patterns of rumination, hopelessness, and withdrawal that become self-reinforcing. In PTSD, fear circuits become hyperactive and overconnected. In addiction, reward pathways become deeply grooved.

These aren't character flaws — they're structural patterns in the brain that become increasingly difficult to change over time. The longer a neural circuit fires in a particular pattern, the harder it is to redirect.

How psychedelics promote plasticity

The research here is converging from multiple directions:

Dendritic spine growth: A landmark 2018 study published in Cell Reports by [Ly and colleagues at UC Davis](https://pubmed.ncbi.nlm.nih.gov/29898390/) showed that psychedelics (including LSD, DMT, DOI, and the ibogaine metabolite noribogaine) promote both spinogenesis and neuritogenesis in cortical neurons — the small projections on neurons where synaptic connections form. In rodent and in vitro models, these structural changes were accompanied by increased synapse number and function and appeared to depend on TrkB, mTOR, and 5-HT2A signaling. More recent mechanistic work by [Vargas, Olson and colleagues (Science, 2023)](https://pubmed.ncbi.nlm.nih.gov/36795823/) showed that the plasticity-promoting effects appear to require activation of intracellular 5-HT2A receptors — which serotonin itself cannot reach — helping explain why psychedelics, but not endogenous serotonin, drive cortical growth.

BDNF release: Psychedelics increase levels of brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival, growth, and new connection formation. BDNF is sometimes called "Miracle-Gro for the brain" — it's the same protein that increases with exercise and is often depleted in depression.

Glutamate surge: Psychedelics trigger a surge of glutamate — the brain's primary excitatory neurotransmitter — in the prefrontal cortex. This glutamate release activates AMPA receptors, which in turn promotes the intracellular signaling cascades that drive neuroplasticity. Ketamine works through a related but distinct glutamate mechanism, which may explain why both classes of drugs promote rapid plasticity.

Default Mode Network disruption: Perhaps the most fascinating finding from brain imaging studies is that psychedelics temporarily reduce activity and connectivity in the Default Mode Network (DMN) — a set of brain regions associated with self-referential thinking, mind-wandering, and ego.

In depression, the DMN tends to be overactive and excessively connected — which maps onto the experience of being stuck in your own head, ruminating, and unable to break free from negative self-narratives. Psychedelics temporarily quiet this network, which may be why people report feeling "released" from their usual patterns of thinking.

The plasticity window

Here's what makes this clinically relevant: the enhanced plasticity doesn't last forever. Research suggests that psychedelics open a "critical period" of heightened plasticity that lasts days to weeks after the experience. During this window, the brain is more malleable — more receptive to forming new patterns.

This is why integration therapy matters so much. The psychedelic opens the window; the therapeutic work done during the plasticity period determines what gets built through it.

A 2023 study from Yale showed that psilocybin increased synaptic density in the prefrontal cortex of humans (measured by PET imaging), with effects persisting for at least one month after a single dose. This was the first direct evidence in living humans that psilocybin produces structural brain changes.

Why this is different from SSRIs

SSRIs also promote neuroplasticity — but more slowly and through different mechanisms. SSRIs gradually increase BDNF levels and promote hippocampal neurogenesis (the birth of new neurons in the memory center). This is one theory for why SSRIs take weeks to work: the brain needs time to grow and integrate new connections.

Psychedelics appear to accelerate this process dramatically. The neuroplasticity effects are measurable within hours, not weeks. And the magnitude of change — at least in animal models — appears larger.

Whether this faster, more intense plasticity produces better long-term outcomes is still being determined. The most-cited clinical signal comes from a small randomized trial by [Davis and colleagues at Johns Hopkins (JAMA Psychiatry, 2021)](https://pubmed.ncbi.nlm.nih.gov/33146667/), in which two psilocybin sessions with supportive psychotherapy produced large reductions in depression scores versus a waiting-list control through 4 weeks of follow-up. Important caveats: only 24 participants completed the intervention, the comparison was a waiting list (not an active or blinded placebo), and durability beyond a month was not assessed in this trial. The mechanistic data nonetheless help explain why psychedelic therapy and conventional antidepressants might ultimately serve different clinical niches: SSRIs for gradual, sustained maintenance; psychedelics for rapid disruption of entrenched patterns.

Non-psychedelic psychoplastogens

Perhaps the most practically significant development in this field isn't psychedelics themselves — it's the search for compounds that promote the same neuroplasticity without the psychedelic experience.

Researchers call these psychoplastogens — drugs that promote neural plasticity without the perceptual and consciousness-altering effects. Several pharmaceutical companies are developing non-hallucinogenic analogs of psychedelic compounds that retain the plasticity-promoting properties.

If successful, these drugs could offer the neurobiological benefits of psychedelic therapy without requiring eight-hour supervised sessions, extensive screening, or the psychological intensity of the experience itself.

A [2020 study in Nature from Cameron, Olson and colleagues at UC Davis](https://pubmed.ncbi.nlm.nih.gov/33299186/) identified a non-hallucinogenic analog of ibogaine called tabernanthalog (TBG) that promoted structural neural plasticity, reduced alcohol- and heroin-seeking behavior, and produced antidepressant-like effects in rodents without the cardiac or hallucinogenic effects of ibogaine itself. These were preclinical findings in animals — human trials of related compounds are now underway, but tabernanthalog has not been proven safe or effective in humans.

What this means for the future

The neuroplasticity story is ultimately more important than any individual psychedelic compound. What we're learning is that the brain has an enormous capacity for rewiring — far more than we appreciated even a decade ago — and that this capacity can be pharmacologically enhanced.

Whether the tools that harness this capacity look like traditional psychedelics, non-hallucinogenic psychoplastogens, precision ketamine protocols, or something we haven't discovered yet is an open question. But the fundamental insight — that depression and PTSD involve treatable structural patterns in the brain, not permanent damage — is already changing how we think about mental illness.

---

This article is for educational purposes. Dr. Kim follows the neuroscience of psychedelics and neuroplasticity as part of staying current in mental health medicine. For evidence-based mental health care available today, [start here](/intake/mental-health).